Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
Duke University · Cardiovascular Institute of the South · +18 more institutions
Abstract
Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear.
inhibitor to receive apixaban or a vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events.
Citation impact
- FWCI
- 126.19
- Percentile
- 100%
- References
- 32
Authors
22- RDRenato D. LópesCorresponding
Duke University, Cardiovascular Institute of the South, Clinical Research Institute
- GHGretchen Heizer
Duke University, Cardiovascular Institute of the South, Clinical Research Institute
- RARonald Aronson
Cardiovascular Institute of the South, Bristol-Myers Squibb (United States)
- ANAmit N. Vora
Duke University, Cardiovascular Institute of the South, Clinical Research Institute
- TMTyler Massaro
Duke University, Cardiovascular Institute of the South, Clinical Research Institute
Topics & keywords
- Medicine
- Antithrombotic
- Conventional PCI
- Acute coronary syndrome
- Percutaneous coronary intervention
- Cardiology
- Atrial fibrillation
- Internal medicine
- Good health and well-being